Rational Design Based Molecular Modeling for Novel Lumiracoxib Analogues: Enhancing The Affinity Toward Cyclooxygenase Type 2 Over Cyclooxygenase Type 1
published by Aِl-Baath University
in 2015
in Pharmacy
and research's language is
العربية
Download
Abstract in English
Compounds, showing selectivity towards COX-2, are
promising agents as selective non-steroidal anti-inflammatory drugs
(NSAIDs) with lower side effects, especially, gastrointestinal ones.
However, recent reports reveal the cardiovascular side effects
associated with the selective COX-2 inhibitors. Therefore, attempts
have been done to develop the second generation of selective COX-2
inheritors. They have safer profile compared to the first generation.
Lumiracoxib belongs to this class of compounds. In this study, the
molecular structure of the target enzymes were prepared. Library of
rationally designed lumiracoxib analogues were docked.
References used
Mysler, E., 2004, Lumiracoxib (Prexige®): a new selective cox-2 inhibitor. International Journal of Clinical Practice. 58(6): p. 606-611
Bombardier, C., et al., 2000, Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis. New England Journal of Medicine. 343(21): p. 1520-15282
Chan, F.K., et al., 2002, Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. New England Journal of Medicine. 347(26): p. 2104-21102